{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of 95% confidence interval (CI) could not be estimated due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"10.6","upperLimit":"NA","value":"15.2"},{"comment":"The upper limit of 95% CI could not be estimated due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"3.7","upperLimit":"NA","value":"6.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"First Line Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.4","upperLimit":"18.7","value":"12.5"},{"comment":"The upper limit of 95% CI could not be estimated due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"2.7","upperLimit":"NA","value":"5.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Second Line Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"DOR: time from date of first radiographic evidence of response (CR/PR) to earliest documented PD per RECIST v1.1 as assessed by response reported by investigator on eCRF, or death by any cause. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis \\<10 mm. PR: \\>=30% decrease under baseline of sum of diameters of all target measurable lesions. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, with minimum absolute increase of 5 mm for target disease or unequivocal progression of pre-existing lesions for non-target disease or any new lesion. DOR for first line and second line is presented. Analysis performed by Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received encorafenib 300 milligrams (mg) once daily (QD) orally (received after Cycle 1 Day 3) and cetuximab 500 mg per square meters (mg/m\\^2) intravenous (IV) infusion for 120 minutes once every 2 weeks (Q2W) along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 180 mg/m\\^2 as IV infusion for 90 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"SLI: Cohort 1 [EC + FOLFIRI]"},{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG001","title":"SLI: Cohort 2 [EC + mFOLFOX6]"}],"paramType":"MEDIAN","populationDescription":"The FAS for SLI included all participants who were randomized in the SLI portion of the study. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure with a confirmed objective response as assessed by investigator and \"Number Analyzed\" signifies participants evaluable for specified rows. All participants under \"Overall Number of Participants Analyzed\" contributed data to the table but may not have data evaluable for each row.","reportingStatus":"POSTED","timeFrame":"From date of first radiographic evidence of response (CR or PR) to earliest documented PD or death due to any cause whichever occurred first (maximum up to 33.9 months)","title":"SLI: Duration of Response (DOR) as Assessed by Investigator According to Line of Therapy - FAS","type":"SECONDARY","unitOfMeasure":"Months"}